阅读说明：本技术 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 (Use of anti-CD 5 Antibody Drug Conjugates (ADCs) in allogeneic cell therapy ) 是由 安东尼·博伊坦诺 迈克尔·库克 于 2019-07-23 设计创作，主要内容包括：本发明提供了在经历嵌合抗原受体(CAR)免疫疗法的人类患者中消耗CD5+细胞以便促进对表达CAR的免疫细胞的接受的方法。将抗CD5抗体药物缀合物(ADC)作为调节方案施用至接受自体或同种异体的表达CAR的免疫细胞的人类患者,使得表达CAR的免疫细胞被人类患者接受。本发明的组合物和方法可以与CAR疗法组合使用,以治疗多种疾病,包括自身免疫性疾病和癌症。(The present invention provides methods of depleting CD5+ cells in a human patient undergoing Chimeric Antigen Receptor (CAR) immunotherapy in order to facilitate the acceptance of CAR-expressing immune cells. Administering an anti-CD 5 Antibody Drug Conjugate (ADC) as a regulatory regimen to a human patient receiving autologous or allogeneic CAR-expressing immune cells, such that the CAR-expressing immune cells are received by the human patient. The compositions and methods of the invention can be used in combination with CAR therapy to treat a variety of diseases, including autoimmune diseases and cancer.)